Skip to main content
. 2013 Dec 21;13:297. doi: 10.1186/1471-2180-13-297

Table 1.

Macrolide/lincosamide resistant Streptococcus agalactiae : distribution of capsular type, MLVA genotypes and antimicrobials resistance features

Isolate Source MLVA Genotypes a Capsular type b Erythromycin resistance phenotype c Erythromycin resistance genes d MIC (μg/mL) e
 
  
  
  
  
 ermA
ermB
mefA/E
DA
 E
15
 Urine
 8
 Ia
 M
 -
 -
 +
 0.06
 4.0
22
 Urine
 8
 Ia
 M
 -
 -
 +
 0.06
 4.0
46
 Urine
 8
 Ia
 M
 -
 -
 +
 0.06
 4.0
120
 Urine
 8
 Ia
 M
 -
 -
 +
 0.06
 4.0
121
 Swab
 8
 Ia
 M
 -
 -
 +
 0.03
 2.0
66
 Urine
 1
 III
 iMLSB
 -
 +
 -
 0.06
 2.0
109
 Urine
 1
 III
 iMLSB
 +
 -
 -
 0.03
 2.0
113
 Urine
 1
 III
 iMLSB
 +
 +
 -
 0.03
 2.0
114
 Urine
 1
 III
 iMLSB
 +
 -
 -
 0.06
 > 8.0
65
 Urine
 4
 V
 iMLSB
 +
 -
 -
 0.06
 4.0
105
 Urine
 3
 V
 iMLSB
 +
 -
 -
 0.06
 8.0
108
 Urine
 6
 V
 iMLSB
 +
 -
 -
 0.06
 8.0
112
 Urine
 6
 V
 iMLSB
 +
 -
 -
 0.06
 4.0
115
 Swab
 7
 V
 cMLSB
 -
 +
 -
 > 8.0
 > 8.0
116
 Swab
 4
 V
 iMLSB
 +
 +
 -
 0.06
 8.0
117 Urine 6 V iMLSB + - - 0.06 4.0

aThe genetic diversity was assessed by MLVA typing [32]. A cutoff value of 85% similarity was applied to define MLVA types. bThe capsular type was identified by multiplex-PCR [43]. cErythromycin resistance phenotype was determined by the double-disk diffusion method [46]. dThe presence of specified gene was determined by PCR. (+) Presence; (-) Absence. eThe minimum inhibitory concentrations (MIC) were determined by the agar-dilution method. Clindamycin (DA); Erythromycin (E).